Recursion PharmaceuticalsRXRX
RXRX
About: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Employees: 800
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
106% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 67
61% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 41
30% more call options, than puts
Call options by funds: $28.3M | Put options by funds: $21.7M
7% more funds holding
Funds holding: 312 [Q4 2024] → 333 (+21) [Q1 2025]
2.41% less ownership
Funds ownership: 79.42% [Q4 2024] → 77.01% (-2.41%) [Q1 2025]
10% less funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 9 (-1) [Q1 2025]
22% less capital invested
Capital invested by funds: $2.06B [Q4 2024] → $1.61B (-$451M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
63%
upside
Avg. target
$8
63%
upside
High target
$8
63%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Needham Gil Blum | 63%upside $8 | Buy Maintained | 6 May 2025 |
Morgan Stanley Vikram Purohit | 63%upside $8 | Equal-Weight Maintained | 10 Apr 2025 |
Financial journalist opinion
Based on 7 articles about RXRX published over the past 30 days
Positive
The Motley Fool
4 days ago
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 1.49%) is slimming down and streamlining. After the biotech updated its strategy to do so on Tuesday, investors became more hopeful on its future, bidding the stock up; it closed 1.6% higher at the end of the day.
Negative
Reuters
4 days ago
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn
Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech industry downturn.
Neutral
GlobeNewsWire
1 week ago
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company Recursion (NASDAQ: RXRX), today announced the open-source release of Boltz-2, a first of its kind biomolecular foundation model. Powered by Recursion's NVIDIA supercomputer for its training and validation, this next-generation AI model achieves best-in-class accuracy in jointly modeling complex structures and binding affinities. Boltz-2 represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1.
Positive
Zacks Investment Research
1 week ago
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
2 weeks ago
Recursion to Participate in Upcoming Investor Conferences
Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
Neutral
Zacks Investment Research
2 weeks ago
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Positive
The Motley Fool
2 weeks ago
3 Monster Stocks to Hold for the Next 10 Years
Most investors are best served by owning high-quality "forever" stocks, even if these stocks are only apt to produce average returns.
Negative
Zacks Investment Research
1 month ago
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Positive
The Motley Fool
1 month ago
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Artificial intelligence (AI) has taken over Wall Street. The leaders in this rapidly growing field are attracting significant attention.
Positive
The Motley Fool
1 month ago
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
The artificial intelligence (AI) revolution is reshaping our world at an unprecedented pace. As AI technology evolves, it's set to fundamentally transform countless industries through enhanced automation, operational efficiency, and dramatic improvements in workforce productivity.
Charts implemented using Lightweight Charts™